Floatz logo

Polyiclc

Glioma, Malignant

Mustafa Khasraw, MBChB, MD, FRCP, FRACPPhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Glioma, Malignant cohort.

Asset / SponsorPhaseRating
gsk1120212
St. Jude Children's Research Hospital
Phase 4B
Durvalumab
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Phase 2B
Pembrolizumab
Essen Biotech
Phase 1/2CCC
Niraparib
Armando Santoro, MD
Phase 1/2CCC
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Phase 1/2CCC

View all 34 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →